Salagen Tablets

Company
MGI Pharma

Approval Status
Approved February 1998

Treatment for
Sjogren's Syndrome

Areas
Dermatology / Plastic Surgery , Eye Health / Ophthalmology , Rheumatology

Salagen Tablets (pilocarpine HCl) has been approved as a treatment for the symptoms of dry mouth resulting from Sjogren's Syndrome, chronic, autoimmune disease.

MGI Pharma conducted two phase III human clinical studies, involving 629 patients, to determine the ability of Salagen Tablets to provide relief for the symptoms of dry mouth caused by Sjogren's Syndrome. Study results showed significant increases in salivary flow following the first dose of Salagen, which was maintained throughout the duration of the study. The studies also showed improvement in overall dry mouth conditions, as well as specific symptoms, including: severity of dry mouth and mouth discomfort; the ability to speak, sleep, and swallow food without drinking; and a decreased use of saliva substitutes. the most common side effects related to the drug were sweating, urinary frequency, chills and flushing.

Salagen_tablets Drug Information

The Salagen_tablets drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top